Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 · adults and children with acute exacerbation of asthma
1 finding from 1 review
PEF (L/min) · adults and children with acute exacerbation of asthma
2 findings from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
MgSO4 + SABA showed no clear difference in admission to hospital at initial presentation compared with SABA (low certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Any adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Lung function · adults and children with acute exacerbation of asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical severity score ‐ Fischl index (120 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
It is very uncertain whether mgSO4 changes admission to hospital at initial presentation compared with SABA (very low certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Pulmonary function % predicted PEF (60 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Clinical severity scores (60 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
MgSO4 + SABA + ipratropium showed no clear difference in admission at first presentation compared with SABA + ipratropium (moderate certainty).
1 finding from 1 review
Patient readmissions · adults and children with acute exacerbation of asthma
MgSO4 + SABA + ipratropium showed no clear difference in readmission (7 to 30 days) compared with SABA + ipratropium (low certainty).
1 finding from 1 review
Serious adverse events (during admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Adverse effects Defined as any adverse event occurring post‐admission · adults and children with acute exacerbation of asthma
1 finding from 1 review
FEV1 % predicted · adults and children with acute exacerbation of asthma
1 finding from 1 review
Intervention not reported
Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention probably leads to lower patients with ≥ 1 exacerbations requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review